What it's for (Indications)
- Amisulpride is an atypical antipsychotic medication primarily indicated for the treatment of schizophrenia, encompassing both its acute and chronic manifestations.
- This includes efficacy against both positive symptoms, such as delusions, hallucinations, and thought disorder, and negative symptoms, which manifest as emotional withdrawal, apathy, and blunted affect.
- It is also used in the management of acute psychotic episodes, providing a comprehensive therapeutic approach to complex psychiatric conditions requiring dopamine receptor modulation.
- The therapeutic utility extends across the spectrum of schizophrenic presentations, aiding in symptom control and functional improvement by targeting key dopaminergic pathways involved in the pathophysiology of the disorder.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage regimen for amisulpride is highly individualized, depending on the severity of symptoms, the specific presentation of schizophrenia (positive vs. negative symptoms), and the patient's renal function. For predominantly positive symptoms, the typical oral dose ranges from 400 mg to 800 mg per day, administered in divided doses. In some cases, for severe acute psychotic episodes, doses may be increased up to 1200 mg per day under strict medical supervision. Conversely, for individuals primarily exhibiting negative symptoms, lower doses, generally between 50 mg and 300 mg daily, are often sufficient. Dosage adjustments are mandatory for patients with renal impairment to prevent drug accumulation and potential toxicity, requiring careful monitoring of creatinine clearance, as amisulpride is primarily renally excreted. Dosing in hepatic impairment is generally not required as it is minimally metabolized. |
Safety & Warnings
Common Side Effects
- Amisulpride can cause a range of side effects, both common and serious.
- Common adverse effects include dose-dependent extrapyramidal symptoms (EPS) such as tremor, rigidity, akathisia, and dystonia, particularly at higher doses.
- Hyperprolactinemia is frequent, leading to symptoms like galactorrhea, amenorrhea, gynecomastia, and sexual dysfunction.
- Other common effects include insomnia, anxiety, agitation, sedation, dizziness, weight gain, constipation, and dry mouth.
- More serious, albeit less common, adverse events encompass QTc prolongation with the potential for fatal cardiac arrhythmias like Torsades de Pointes, neuroleptic malignant syndrome (NMS), seizures, agranulocytosis or other blood dyscrasias, and tardive dyskinesia, which may persist after discontinuation.
- Venous thromboembolism (VTE) risk is also a significant concern, necessitating vigilance and appropriate preventive measures, especially in patients with known risk factors.
Serious Warnings
- Black Box Warning: **SERIOUS WARNINGS: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS, QT PROLONGATION, AND NEUROLEPTIC MALIGNANT SYNDROME.** Antipsychotic medications, including amisulpride, are associated with an increased risk of death when used in elderly patients with dementia-related psychosis. Amisulpride is not approved for the treatment of patients with dementia-related psychosis. Furthermore, amisulpride can cause dose-dependent prolongation of the QT interval, which can lead to serious and potentially fatal ventricular arrhythmias, including Torsades de Pointes. This risk is heightened in patients with pre-existing cardiac conditions, electrolyte imbalances, or those concurrently taking other QT-prolonging drugs. Close cardiac monitoring, including ECGs and electrolyte checks, is imperative. Neuroleptic Malignant Syndrome (NMS), a rare but life-threatening idiosyncratic reaction characterized by high fever, muscle rigidity, altered mental status, and autonomic instability, has been reported with antipsychotic use. Immediate discontinuation of amisulpride and intensive symptomatic treatment are required if NMS is suspected. Cerebrovascular adverse events, including stroke and transient ischemic attack, have also been observed in elderly patients with dementia treated with some antipsychotics.
- Several critical warnings are associated with amisulpride use.
- Patients should be closely monitored for QTc prolongation, a risk factor for life-threatening cardiac arrhythmias; baseline and periodic ECGs are recommended, especially in patients with pre-existing cardiac conditions or those on concomitant QTc-prolonging medications.
- Neuroleptic Malignant Syndrome (NMS), a rare but potentially fatal reaction, requires immediate drug discontinuation and supportive care.
- The risk of tardive dyskinesia, characterized by involuntary movements, necessitates regular monitoring and consideration of treatment modification if it emerges.
- There is an increased risk of cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis treated with antipsychotics, though amisulpride is not indicated for this population.
- Seizure threshold may be lowered, requiring caution in patients with a history of epilepsy.
- Venous thromboembolism (VTE) has been reported with antipsychotics, including amisulpride; thus, risk factors for VTE should be identified and preventive measures taken.
- Additionally, orthostatic hypotension may occur, particularly at the initiation of treatment or during dose escalation.
How it Works (Mechanism of Action)
Amisulpride exerts its therapeutic effects primarily through highly selective antagonism of dopamine D2 and D3 receptors. At lower dosages (e.g., 50-300 mg/day), amisulpride preferentially blocks presynaptic D2/D3 autoreceptors. This blockade leads to an increase in dopamine release and enhanced dopaminergic transmission, which is hypothesized to ameliorate negative symptoms of schizophrenia and may have antidepressant properties. At higher dosages (e.g., 400-1200 mg/day), amisulpride blocks postsynaptic D2 and D3 receptors in the mesolimbic system, effectively reducing excessive dopaminergic activity. This action is crucial for controlling positive symptoms of schizophrenia such as hallucinations and delusions. Unlike many other antipsychotics, amisulpride exhibits low affinity for α1-adrenergic, H1-histamine, and muscarinic cholinergic receptors, which contributes to a more favorable side effect profile regarding sedation, orthostatic hypotension, and anticholinergic effects, distinguishing it from older typical antipsychotics.
Commercial Brands (Alternatives)
No other brands found for this formula.